Solana Co
Close on Oct 19, 2026
- Market cap
- $178.66M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 17, 2026, during market hours (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 14, 2026 | During market hours | $2.50M | $-0.38 | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 15, 2026 | During market hours | $3.60M | $-1.30 | – |
| Q4 FY2025 Ended Dec 31, 2025 | Mar 31, 2026 | During market hours | $5.20M | $4.25 | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 18, 2025 | During market hours | – | $-32.89 | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 12, 2024 | During market hours | $182.00K | – | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 13, 2024 | During market hours | $135.00K | $-3.08 | – |
| Q4 FY2023 Ended Dec 31, 2023 | Mar 28, 2024 | During market hours | $134.00K | $-1.47 | – |
| Q3 FY2023 Ended Sep 30, 2023 | Nov 9, 2023 | During market hours | $143.00K | $-5.49 | – |
| Q2 FY2023 Ended Jun 30, 2023 | Aug 10, 2023 | During market hours | – | – | – |
| Q1 FY2023 Ended Mar 31, 2023 | May 11, 2023 | During market hours | – | – | – |
| Q4 FY2022 Ended Dec 31, 2022 | Jan 23, 2023 | Before market open | – | – | – |
Press releases
Announcements Solana filed with the SEC
Solana Company (NASDAQ: HSDT) Announces Pricing of $15 Million Registered Direct Offering with a Global Institutional Investor
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Solana Company Reports Second Quarter 2026 Financial Results
Results of operations · EX-99.1 to Form 8-K
Solana Company Reports First Quarter 2026 Financial Results
Results of operations · EX-99.1 to Form 8-K
Solana Company (NASDAQ: HSDT) Announces Registered Direct Offering of Common Stock to Global Institutional Investor
Unregistered share sale · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Solana Company (NASDAQ: HSDT) Appoints Madelene Gani as Chief Operating Officer and Deputy CFO to Lead Next Phase of Growth
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Solana Company Reports Fourth Quarter and Full Year 2025 Financial Results
Results of operations · EX-99.1 to Form 8-K
Solana Company Reports Third Quarter 2025 Financial Results
Results of operations · EX-99.1 to Form 8-K
Joseph Chee, Executive Chairman [email protected]
Executive or director change · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Solana Company (NASDAQ: HSDT) Releases Investor Update
Executive or director change · Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
destroy all copies of this presentation or portions thereof in its possession promptly following request for the return or destruction of such copies. By accepting delivery of this presentation, the recipient is deemed to agree to the foregoing confidentiality requirements.
Regulation FD disclosure · EX-99.1 to Form 8-K
Solana Company (NASDAQ: HSDT) Releases Investor Update
Regulation FD disclosure · EX-99.2 to Form 8-K
Solana Company Announces Updated SOL Holdings and Industry Leading Staking Yield
Regulation FD disclosure · EX-99.1 to Form 8-K
Solana Company Executive Chairman’s Message: October 20th, 2025
Regulation FD disclosure · EX-99.1 to Form 8-K
Preeminent SOL Treasury Company Helius (NASDAQ:HSDT)
Charter or bylaw amendment · Other events · EX-99.1 to Form 8-K
Helius Announces FDA 510(k) Submission for PoNS® Device Label Expansion in Stroke
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
(NASDAQ:HSDT) Begins Purchases of SOL, the Native Asset of Solana Blockchain
Regulation FD disclosure · EX-99.1 to Form 8-K
(NASDAQ:HSDT), in Partnership with Pantera Capital and Summer Capital
Material agreement · Unregistered share sale · Executive or director change · Charter or bylaw amendment · Regulation FD disclosure · EX-99.1 to Form 8-K
in Partnership with Pantera Capital and Summer Capital
Material agreement · Unregistered share sale · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Strictly Private & Confidential Project Sumtera Investor Presentation September 2025
Material agreement · Unregistered share sale · Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Risks Related to Our Solana and Digital Asset
Material agreement · Unregistered share sale · Regulation FD disclosure · Other events · EX-99.3 to Form 8-K
Unaudited Condensed Interim Consolidated Balance Sheet
Other events · EX-99.1 to Form 8-K
Medical Technologies, Inc. Compliant with Nasdaq Bid Price Rule Listing Criteria
Other events · EX-99.1 to Form 8-K
Helius Medical Technologies Announces Reverse Stock Split
Charter or bylaw amendment · Other events · EX-99.1 to Form 8-K
Helius Medical Technologies, Inc. Announces Exercise of Warrants and Issuance of New Warrants in a Private Placement for $3.7 Million Gross Proceeds Priced At-the-Market
Material agreement · Unregistered share sale · Regulation FD disclosure · EX-99.1 to Form 8-K
Helius Announces First Portable Neuromodulation Stimulator (PoNS ® ) System Sale to the Veterans Affairs (VA) Healthcare System
Other events · EX-99.1 to Form 8-K
Helius Medical Technologies, Inc. Announces Exploration of Strategic Alternatives
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Helius Medical Technologies, Inc. Provides Updates on Efforts to Achieve Fair Market Access for its Portable Neuromodulation Stimulator (PoNS®) Device
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Helius Medical Technologies, Inc. Reports Second Quarter 2024 Financial Results
Results of operations · EX-99.1 to Form 8-K
Helius Medical Technologies, Inc. Reports First Quarter 2024 Financial Results
Results of operations · EX-99.1 to Form 8-K
Announces Pricing of $6.4 Million Public Offering
Material agreement · Other events · EX-99.1 to Form 8-K
Helius Medical Technologies, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results
Results of operations · EX-99.1 to Form 8-K
Helius Medical Technologies, Inc. Secures HCPCS Codes for Portable Neuromodulation Stimulator (PoNS®) Mouthpiece and Controller
Other events · EX-99.1 to Form 8-K
PoNS TherapyTM for Balance and Gait Deficits in Patients with
Regulation FD disclosure · EX-99.1 to Form 8-K
Helius Medical Technologies, Inc. Reports Third Quarter 2023 Financial Results
Results of operations · EX-99.1 to Form 8-K
Helius Medical Technologies, Inc. to Release Third Quarter 2023 Financial Results on November 9, 2023; Announces Extended Cash Runway into Q2 2024
Results of operations · EX-99.1 to Form 8-K
Helius Medical Technologies, Inc. Receives
Other events · EX-99.1 to Form 8-K
Helius Medical Technologies, Inc. Compliant with All Applicable Nasdaq Listing Criteria
Other events · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Charter or bylaw amendment · Other events · EX-99.1 to Form 8-K
Helius Medical Technologies, Inc. Reports Second Quarter 2023 Financial Results
Results of operations · EX-99.1 to Form 8-K